Beta-blockers, renin-angiotensin system inhibitors, and cardiovascular outcomes during trastuzumab therapy for HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials.
- DOI
- 10.21037/tcr-2026-1107
- Published
- 2026 Oct 30
- Container
- Translational cancer research
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.21037/tcr-2026-1107,
title = {Beta-blockers, renin-angiotensin system inhibitors, and cardiovascular outcomes during trastuzumab therapy for HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials.},
author = {Liu Y and Zhang L and Guan J and Wang Z and Luan X},
year = {2026},
journal = {Translational cancer research},
doi = {10.21037/tcr-2026-1107},
url = {https://doi.org/10.21037/tcr-2026-1107}
}RIS
TY - JOUR TI - Beta-blockers, renin-angiotensin system inhibitors, and cardiovascular outcomes during trastuzumab therapy for HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials. AU - Liu Y AU - Zhang L AU - Guan J AU - Wang Z AU - Luan X PY - 2026 JO - Translational cancer research DO - 10.21037/tcr-2026-1107 UR - https://doi.org/10.21037/tcr-2026-1107 ER -
APA
Y, L., L, Z., J, G., Z, W., & X, L. (2026). Beta-blockers, renin-angiotensin system inhibitors, and cardiovascular outcomes during trastuzumab therapy for HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials.. Translational cancer research. https://doi.org/10.21037/tcr-2026-1107
Source records
- pubmed · retrieved 2026-11-10T12:05:10.542Z